SCHEMBL12284542

SCHEMBL12284542

COCCn1c(-c2cnc(-c3ccc(Cl)cc3)[nH]2)nc2ccccc21

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 1/20 0.66
▸ HPGD P15428 2/20 0.56
▸ CASR P41180 1/20 0.55
▸ KDM4E B2RXH2 5/20 0.55
▸ ALDH1A1 P00352 3/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ HSD17B10 Q99714 2/20 0.52
▸ RECQL P46063 1/20 0.52
▸ BRD4 O60885 1/20 0.47
▸ TP53 P04637 3/20 0.47
▸ SCN2A Q99250 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ GRM2 Q14416 1/20 0.45
▸ NPC1 O15118 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12284277 0.88 RIPK2 (0.64) RIPK2HPGDCASRKDM4EALDH1A1
SCHEMBL14616781 0.88 RIPK2 (0.64) RIPK2HPGDCASRKDM4EALDH1A1
SCHEMBL14616779 0.88 RIPK2 (0.72) RIPK2HPGDCASRKDM4EALDH1A1
SCHEMBL14616778 0.86 RIPK2 (0.62) RIPK2HPGDCASRKDM4EALDH1A1
SCHEMBL14616777 0.84 RIPK2 (0.67) RIPK2HPGDCASRKDM4EHSD17B10
SCHEMBL14616784 0.83 RIPK2 (0.71) RIPK2
SCHEMBL14616773 0.82 RIPK2 (0.83) RIPK2KDM4EDRD2TBXA2R
SCHEMBL14616801 0.82 RIPK2 (0.49) RIPK2HPGDCASRKDM4EALDH1A1
SCHEMBL14616783 0.81 RIPK2 (0.73) RIPK2KDM4EALDH1A1TP53MAPT
SCHEMBL14616775 0.81 RIPK2 (0.84) RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
WO-2011123609-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 RIPK2 255/4885HPGD 3449/4885CASR 2479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback